摘要
目的:探讨PET/CT显像对霍奇金淋巴瘤(Hodgkin's lymphoma,HD)化疗中期疗效评价的作用。方法:回顾性分析医院2005年至2011年病理活检和免疫组化确诊的42例HD患者的^(18)F-FDG PET/CT显像结果,应用无进展生存(progressionfree survival,PFS)期及总体生存(overall survival,OS)期作为随访指标,进行疗效评价。组间PFS率及OS率的比较采用χ~2检验;预后的单因素分析采用Kaplan-Meier生存分析法。结果:42例患者化疗两疗程后行^(18)F-FDG PET/CT显像,结果阳性者和阴性者中位PFS期分别为12个月和42个月,两年PFS率分别为10%(2/20)和68.1%(15/22),差异有统计学意义(χ~2=14.719,P=0.000);中位OS期分别为20个月和44个月,两年OS率分别为35%(7/20)和81.8%(18/22),差异有统计学意义(χ~2=9.531,P=0.002)。结论:中期PET/CT显像对HD患者疗效评价及预后判断具有重要意义。
Objective： To investigate the value of PET/CT in monitoring response to interim therapy for Hodgkin＇ s lymphoma patients. Methods： A retrospective study was perfomaed in 18F-FDG PET/CT for 42 patients with Hodgkin＇ s lymphoma from 2005 to 2011 in our hospital. PET/CT status was assessed for its ability to predict progression-free survival （PFS） and overall survival （OS）. We used the chi-square test and Kaplan-Meier estimates for data analysis. Results： 42patients received 18F-FDG PET/CT after 2 cycles of chemotherapy, the median PFS in patients with positive and negative group were I2 months and 42 months, 2-year PFS rate were 10% （2/20） and 68.1%（15/22）, respectively; the median OS were 20 months and 44months, and 2-year OS rate were 35% （7/20） and 81.8% （18/22）, respectively, all being of significant difference between two groups （X^2=14.719, P=0.000 ; X^2=9-531 P=0.002, respectively）. Conclusion： Interim PET/CT imaging has significant value in monitoring response to therapy and predicting prognosis for patients with Hodgkin＇ s lymphoma.
出处
《中国数字医学》
2016年第4期76-78,共3页
China Digital Medicine
